Craig Hallum Initiates Coverage on Compass Therapeutics (NASDAQ:CMPX)

Craig Hallum initiated coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a report released on Friday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $15.00 price target on the stock. Craig Hallum’s target price indicates a potential upside of 138.85% from the company’s current price.

CMPX has been the topic of several other reports. Citigroup started coverage on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. They issued an “outperform” rating on the stock. Leerink Partners raised shares of Compass Therapeutics to a “strong-buy” rating in a report on Wednesday, November 26th. Canaccord Genuity Group set a $13.00 target price on shares of Compass Therapeutics in a report on Wednesday, February 4th. D. Boral Capital reiterated a “buy” rating and issued a $30.00 price target on shares of Compass Therapeutics in a research report on Tuesday, January 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Compass Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $13.00.

Compass Therapeutics Price Performance

Shares of NASDAQ CMPX opened at $6.28 on Friday. The stock’s fifty day moving average price is $5.67 and its two-hundred day moving average price is $4.50. Compass Therapeutics has a one year low of $1.33 and a one year high of $6.88. The firm has a market cap of $1.12 billion, a price-to-earnings ratio of -13.96 and a beta of 1.46.

Institutional Investors Weigh In On Compass Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP bought a new position in shares of Compass Therapeutics in the 4th quarter valued at $6,786,000. The Manufacturers Life Insurance Company boosted its stake in Compass Therapeutics by 21.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 40,325 shares of the company’s stock valued at $217,000 after buying an additional 7,164 shares in the last quarter. Stifel Financial Corp bought a new position in Compass Therapeutics in the fourth quarter valued at about $129,000. Rafferty Asset Management LLC raised its stake in Compass Therapeutics by 113.8% during the fourth quarter. Rafferty Asset Management LLC now owns 151,743 shares of the company’s stock worth $815,000 after acquiring an additional 80,784 shares in the last quarter. Finally, Birchview Capital LP lifted its holdings in shares of Compass Therapeutics by 82.5% in the fourth quarter. Birchview Capital LP now owns 1,592,938 shares of the company’s stock worth $8,554,000 after acquiring an additional 720,000 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.